Skip to content
Review Open access

The Molecular, Genetic, Pathological Basis and Clinical Perspectives of Endometrial Cancer: A Narrative Review

Oct 2026 · International Journal of Molecular Sciences · Vol 27, pp. 9511 · 0 citations

TL;DR

Integrating multi-omics techniques, artificial intelligence, and novel systemic therapies into clinical workflows emerge to refine risk stratification, avoid over- or undertreatment, and establish a new standard of precision oncology in endometrial cancer.

Abstract

Endometrial cancer (EC) is the most common gynecologic malignancy in high-income regions, with a rising global incidence driven by population aging and obesity. Management of EC is undergoing a paradigm shift from traditional histopathological classification (Bokhman Types I and II) to a molecularly integrated model. Key driver alterations include mutations in PTEN, PIK3CA, PIK3R1, ARID1A, KRAS, and TP53, alongside focal amplifications of CCNE1 and ERBB2, all of which drive oncogenesis through dysregulation of the PI3K/AKT/mTOR, Wnt/β-catenin, MAPK/ERK, and p53 signaling cascades. Integrated genomic profiling via The Cancer Genome Atlas (TCGA) and practical surrogates like ProMisE classifies EC into four distinct molecular subgroups: POLE-ultramutated (POLEmut), mismatch repair-deficient (MMRd/MSI-H), copy-number low/non-specific molecular profile (NSMP), and copy-number high/p53-abnormal (p53abn). These subgroups display unique biological features, tumor microenvironments, and prognostic trajectories, and have been formally incorporated into the FIGO 2023 staging system. Crucially, molecular classification directly informs biomarker-driven systemic management. MMRd may predict profound responses to immune checkpoint inhibitors (e.g., pembrolizumab, dostarlimab) in both frontline and recurrent settings. For MMR-proficient disease, combination strategies such as anti-angiogenic/immunotherapy (lenvatinib plus pembrolizumab), hormone/mTOR or CDK4/6 inhibitor combinations, and nuclear export inhibitors (selinexor in TP53 wild-type) seem to offer substantial benefit. Furthermore, novel modalities including HER2-targeted antibody-drug conjugates (trastuzumab deruxtecan), PARP inhibitors, and G2/M checkpoint inhibitors (adavosertib) are actively expanding the therapeutic armamentarium. Integrating multi-omics techniques, artificial intelligence, and novel systemic therapies into clinical workflows emerge to refine risk stratification, avoid over- or undertreatment, and establish a new standard of precision oncology in endometrial cancer.

Read PDF

Similar papers

Clinical trial Open access Oct 2026

PIK3CA Mutations in Advanced or Recurrent Endometrial Cancer: An Exploratory Molecular Profiling From the Phase II MITO END-3 Study

Purpose Immunotherapy with chemotherapy significantly improves progression-free survival in advanced endometrial cancer (EC), especially in microsatellite instability-high (MSI-H) cases. Despite this, for recurrent EC in the postimmunotherapy setting, new treatment options are urgently needed. The PI3K pathway is frequ...

A. Passarelli, G. L. Scaglione, D. Califano et al. · 0 citations
Review Open access Sep 2026

Beyond molecular classification: integrating signaling, subcellular, and immune reprogramming in endometrial cancer

This narrative review synthesizes current evidence across several interconnected dimensions of EC biology and proposes an integrated conceptual model in which developmental signaling, subcellular protein trafficking, epigenetic and stemness reprogramming, and immune remodeling are mechanistically coupled, rather than i...

Miłosz Pietrus, Marcin Waligóra, M. Socha et al. · 0 citations
Review Sep 2026

Uterine Carcinosarcoma: Mutational Profiling of p53-Abnormal Tumors and Its Association with Histologic Subtypes and Survival in an Underserved Population.

Uterine carcinosarcoma is a rare and highly aggressive malignancy characterized by biphasic epithelial and mesenchymal components. Although molecular classification has improved risk stratification in endometrial carcinoma, the mutational profile of carcinosarcoma by heterologous versus homologous sarcomatous component...

Jing Zhou, M. Yassa, D. Yu et al. · 0 citations
Review Open access Oct 2026

MOLECULAR PORTRAIT OF ORAL SQUAMOUS CELL CARCINOMA: GENETIC DRIVERS, BIOMARKERS, AND THERAPEUTIC TARGETS

Oral squamous cell carcinoma (OSCC) remains one of the most burdensome malignancies of the head and neck region, with roughly 390,000 new cases and nearly 190,000 deaths estimated annually worldwide. Its five-year survival has stagnated near 50% despite refinements in surgery and radiotherapy. Histological grading and...

Asiyat Rustamovna Buttaeva, Khadzhimurad Makhachevich Khaybulaev, Ibragim Rabadanovich Rabadanov et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.